Mirum Pharmaceuticals

World Rank (Jan-05-2024)

7,121

Market Cap (Jan-05-2024)

1.384 Billion USD

World Rank (Jul-30-2023)

8,800

Market Cap (Jul-30-2023)

0.988 Billion USD

World Rank (Jan-07-2022)

13,731

Market Cap (Jan-07-2022)

0.477 Billion USD

World Rank (Jan-01-2021)

11,018

Market Cap (Jan-01-2021)

0.514 Billion USD

Headquarters Country

USA

Nasdaq / NYSE Code

MIRM

Market Cap (Mar-08-2026)

5.21

Employee Count

137

Employee Count as of Date

As on 2021

Headquarters City/State

California

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

77 Million USD

Annual Operating Income in USD

-131 Million USD

Annual Net Income in USD

-135 Million USD

Annual Results for Period Ending

Dec-2022 ending year

Total Assets in USD

352 Million USD

Total Liabilities in USD

210 Million USD

Total Equity in USD

142 Million USD

Balance Sheet for Period Ending

Dec-2022 ending year

Business Sector

Company Website

MIRUM PHARMACEUTICALS

Yahoo

Yahoo @ Nasdaq

Company Profile

Mirum Pharmaceuticals is a Clinical Stage Biopharmaceutical company focused on clinical studies for the treatment of cholestatic diseases including primary sclerosing cholangitis (PSC), intrahepatic cholestasis of pregnancy (ICP) and primary biliary cholangitis (PBC). It is having 24 employees as on 2019. The headquarters is in USA.

Founded Year

2018

IPO Year

2019

Stock Exchange

Nasdaq

Nasdaq Sector

Health Care

Nasdaq Industry

Biotechnology: Pharmaceutical Preparations